Form 10-Q · Quarterly report
Revvity 10-Q, filed Aug 11, 2026
- Filed
- CIK
- 0000031791
- Accession no.
- 0000031791-26-000027
Summary
Revvity reported second-quarter fiscal 2026 revenue of $729.7 million, up 1% from $720.3 million a year earlier, as Diagnostics segment revenue rose 5% while Life Sciences fell 2% on weaker Software revenue. Gross margin rose 260 basis points to 57.1%, helped by tariff refunds and product mix, while operating margin slipped to 12.2% from 12.6% amid restructuring charges tied to workforce reductions affecting about 3% of employees.
Key points
- Revenue for the quarter ended July 5, 2026 was $729.7 million, up $9.4 million or 1% year over year, with Diagnostics up 5% to $371.0 million and Life Sciences down 2% to $358.7 million.
- Gross margin increased 260 basis points to 57.1%, primarily due to tariff refunds and product mix shift; operating margin decreased to 12.2% from 12.6% on restructuring charges and digital investments.
- After the U.S. Supreme Court ruled in February 2026 that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied for $20.2 million of refunds through the CBP process and recorded $16.2 million received through July 5, 2026 in cost of revenue.
- Restructuring and other costs were $35.5 million in the quarter, mainly for workforce reductions and facility consolidations affecting approximately 3% of the workforce.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2.Management’s Discussion Overview Our fiscal year ends on the Sunday nearest December 31. We report fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending January 3, 2027 (“fiscal year 2026”) will include 53 weeks, and the fiscal year ended December 28, 2025 (“fiscal year 2025”) included 52 weeks. We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.